A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms Colon II
- Sponsors AB Science
- 15 Jun 2019 Trial has been completed in France, according to European Clinical Trials Database record.
- 30 Apr 2018 According to an AB Science media release, Results of the trend analysis are expected in 2018.
- 25 Apr 2018 This study has been completed in Spain.